Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024

7/15/24 4:01:00 PM ET

Computer Manufacturing

Technology

Get the next $OMCL alert in real time by email

Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the second quarter 2024, before market open on Thursday, August 1, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3278878. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/.

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

OMCL-E

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715945122/en/

Get the next $OMCL alert in real time by email

Recent Analyst Ratings for

$OMCL

Date	Price Target	Rating	Analyst
10/31/2024	$44.00 → $57.00	Buy → Neutral	BofA Securities
8/2/2024	$26.00 → $39.00	Underweight → Equal Weight	Barclays
1/3/2024	$33.00	Underweight	Barclays
11/3/2023	$39.00 → $28.00	Underweight → Equal Weight	Wells Fargo
11/3/2023		Buy → Neutral	BTIG Research
11/3/2023	$70.00 → $39.00	Neutral → Overweight	Piper Sandler
10/11/2023		Overweight → Sector Weight	KeyBanc Capital Markets
9/26/2023	$56.00 → $39.00	Underweight	Wells Fargo

More analyst ratings

Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024

Chat with this insight

Recent Analyst Ratings for
$OMCL

$OMCL
Press Releases

Fastest customizable press release news feed in the world

Omnicell Announces First Quarter 2025 Results

Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

$OMCL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Operating Officer Njoku Nnamdi was granted 37,409 shares, increasing direct ownership by 70% to 90,929 units (SEC Form 4)

CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J was granted 22,445 shares and covered exercise/tax liability with 71 shares, increasing direct ownership by 23% to 120,281 units (SEC Form 4)

$OMCL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

$OMCL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Omnicell downgraded by BofA Securities with a new price target

Omnicell upgraded by Barclays with a new price target

Barclays initiated coverage on Omnicell with a new price target

$OMCL
Financials

Live finance-specific insights

$OMCL
Leadership Updates

Live Leadership Updates

Omnicell Announces First Quarter 2025 Results

Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

Omnicell Elects Eileen Voynick to Board of Directors

$OMCL
SEC Filings

SEC Form 10-Q filed by Omnicell Inc.

Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by Omnicell Inc.

$OMCL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024

Chat with this insight

Recent Analyst Ratings for $OMCL

$OMCL Press Releases

Fastest customizable press release news feed in the world

Omnicell Announces First Quarter 2025 Results

Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

$OMCL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Operating Officer Njoku Nnamdi was granted 37,409 shares, increasing direct ownership by 70% to 90,929 units (SEC Form 4)

CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J was granted 22,445 shares and covered exercise/tax liability with 71 shares, increasing direct ownership by 23% to 120,281 units (SEC Form 4)

$OMCL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

$OMCL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Omnicell downgraded by BofA Securities with a new price target

Omnicell upgraded by Barclays with a new price target

Barclays initiated coverage on Omnicell with a new price target

$OMCL Financials

Live finance-specific insights

$OMCL Leadership Updates

Live Leadership Updates

Omnicell Announces First Quarter 2025 Results

Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

Omnicell Elects Eileen Voynick to Board of Directors

$OMCL SEC Filings

SEC Form 10-Q filed by Omnicell Inc.

Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by Omnicell Inc.

$OMCL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

Recent Analyst Ratings for
$OMCL

$OMCL
Press Releases

$OMCL
Insider Trading

$OMCL
Large Ownership Changes

$OMCL
Analyst Ratings

$OMCL
Financials

$OMCL
Leadership Updates

$OMCL
SEC Filings

$OMCL
Insider Purchases